MajorPharmacokinetic enhancer (booster) for antiretroviral therapy×Triptan, selective 5HT1B/1D receptor agonist
Updated · Methodology
Mechanism
The liver breaks down eletriptan mainly through the enzyme CYP3A4. Cobicistat is a strong CYP3A inhibitor, and that is its purpose: it raises atazanavir or darunavir levels. The labels give no study of this exact pair, so the closest guide is data on other strong inhibitors. Ketoconazole 400 mg raised the eletriptan area under the curve (AUC) 5.9-fold and lengthened its half-life from 4.8 to 8.3 hours. Erythromycin 1000 mg raised the AUC 3.6-fold. Because of this rise in exposure, the labels do not allow eletriptan with strong CYP3A4 inhibitors. Like other triptans, eletriptan narrows blood vessels and can cause coronary artery spasm.
Symptoms
Tightness, pain or pressure in the chest, throat, neck and jaw is common after eletriptan. It is usually not cardiac but can be a sign of coronary artery spasm. Myocardial infarction, ventricular tachycardia and ventricular fibrillation have occurred within a few hours of triptan use, sometimes in people without known heart disease. Rarely, blood pressure rises sharply, even to a hypertensive crisis. Spasm of other arteries can cause Raynaud's syndrome or bowel ischaemia with abdominal pain and bloody diarrhoea. Stroke and brain haemorrhage have occurred after triptans.
Management
The eletriptan summary of product characteristics (SmPC) says not to use eletriptan with strong inhibitors of the enzyme CYP3A4 (Spanish Agency of Medicines and Medical Devices, AEMPS). The cobicistat SmPC calls cobicistat a strong CYP3A inhibitor (European Medicines Agency, EMA). Do not give eletriptan while the patient takes cobicistat or for at least 72 hours after the last dose (eletriptan label, US Food and Drug Administration, FDA). This also applies to tablets that combine cobicistat with atazanavir or darunavir, because the cobicistat interactions carry over to these products (Evotaz and Rezolsta SmPCs, EMA). If eletriptan has been taken and chest pain or tightness suggesting cardiac ischaemia appears, give no further doses and evaluate the heart (eletriptan SmPC, AEMPS). Stop eletriptan if arrhythmias occur and monitor blood pressure during treatment (eletriptan label, FDA). If signs of spasm in other arteries appear, such as abdominal pain with blood in the stool or white, cold fingers, rule out vasospasm before the next dose (eletriptan label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Relpax (eletriptan hydrobromide) tablets – prescribing information (2024)– FDA label, Viatris Specialty, DailyMed setid 2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e, version 4, 01/2024, sections 4, 5.7, 7.1, 7.2 and 7.3
- AEMPS: Ficha técnica: Eletriptán (nº registro 64124), sección 4.5 (2024)– AEMPS, CIMA, nº registro 64124 (Relpax 20 mg, Viatris), revisión 05/2024, secciones 4.4 y 4.5
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5